---
title: "Attovia Therapeutics, Inc. (ATTO) Initiated with a Buy at RBC Capital"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297470988.md"
description: "Attovia Therapeutics, Inc. received a Buy rating and a $45.00 price target from RBC Capital analyst Brian Abrahams yesterday. According to TipRanks, Abrahams is a 5-star analyst with an average return of 15.0% and a 56.31% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Definium Therapeutics, and Biogen. Attovia Therapeutics, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $45.00."
datetime: "2026-08-31T06:25:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297470988.md)
  - [en](https://longbridge.com/en/news/297470988.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297470988.md)
generator: "portal-rs"
---

# Attovia Therapeutics, Inc. (ATTO) Initiated with a Buy at RBC Capital

Attovia Therapeutics, Inc. received a Buy rating and a $45.00 price target from RBC Capital analyst Brian Abrahams yesterday.

According to TipRanks, Abrahams is a 5-star analyst with an average return of 15.0% and a 56.31% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Definium Therapeutics, and Biogen.

Attovia Therapeutics, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $45.00.

### Related Stocks

- [ATTO.US](https://longbridge.com/en/quote/ATTO.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)

## Related News & Research

- [Attovia Therapeutics, Inc.'s (NASDAQ:ATTO) Quiet Period To End  on September 14th](https://longbridge.com/en/news/298168859.md)
- [Sam Slutsky Reiterates Buy on Attovia, Maintains $45 Price Target on Strong Early ATTO-1310 Data and Robust Cash Runway](https://longbridge.com/en/news/297940103.md)
- [Attovia's Q2 Loss Expands With Increased Trials For ATTO-1310; Plans Phase 2 For Q1 '27](https://longbridge.com/en/news/297941843.md)
- [McRae Industries, Inc. declares $0.14 dividend](https://longbridge.com/en/news/298227975.md)
- [Egetis Therapeutics CEO to join fireside chats at Cantor, Morgan Stanley healthcare conferences](https://longbridge.com/en/news/297867901.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**